GH Stock Analysis: Guardant Health | NASDAQ

Liquid Biopsy, Tissue Testing, Cancer Screening, Genomic Analytics

Total Rating 46

Safety 38

Buy Signal 0.43

Diagnostics & Research
Industry Rotation: +0.6

Market Cap: 22.6B
Avg Turnover: 296M

Risk 3d forecast

Volatility60.1%

VaR 5^th Pctl9.64%

VaR vs Median-2.67%

Reward TTM

Sharpe Ratio2.14

Rel. Str. IBD97.6

Rel. Str. Peer Group88.3

Character TTM

Beta1.264

Beta Downside0.459

Hurst Exponent0.498

Drawdowns 3y

Max DD59.79%

CAGR/Max DD1.14

CAGR/Mean DD3.22

EPS (Earnings per Share)

Last SUE: -1.46
Qual. Beats: -1

Revenue

Rev. CAGR: 32.73%
Rev. Trend: 99.6%

Last SUE: 3.10
Qual. Beats: 9

Warnings

Negative Equity With Losses

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 7.8 years of data

Jan +6.0% 9

Feb -10.2% 28

Mar -4.4% 6

Apr -1.5% 24

May +7.9% 9

Jun +8.0% 29

Jul +2.2% 9

Aug +4.8% 17

Sep -3.8% 20

Oct -3.4% 26

Nov +5.4% 25

Dec -7.2% 42

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: GH Guardant Health

Guardant Health, Inc. (NASDAQ: GH) is a precision oncology company that develops blood and tissue tests, alongside related data products, serving customers in the United States and internationally. Founded in 2011 and headquartered in Palo Alto, California, the company went public in October 2018. Guardant operates in the Health Care Services sub-industry and is classified as a large-cap stock.

The companys commercial test menu centers on liquid biopsy and tissue-based molecular profiling. Key offerings include the Guardant360 CDx (a companion diagnostic for tumor mutation profiling), the Guardant360 Liquid and Guardant360 Tissue tests, the Guardant Reveal ctDNA-based test for residual disease monitoring, and the Shield blood test for colorectal cancer screening in adults. Companion diagnostics like Guardant360 CDx are regulatory-cleared tests used by oncologists to identify patients likely to respond to specific targeted therapies, a core component of the precision oncology business model.

In addition to its clinical tests, Guardant provides research-use products (GuardantINFINITY, GuardantOMNI, and GuardantINFORM), the GuardantConnect software platform for clinical trial enrollment, and its Smart Platform for multiomic research. The company also offers companion diagnostic development and regulatory services to biopharmaceutical partners, and maintains a strategic collaboration with Nuvalent, Inc. for oncology drug development, reflecting the integrated diagnostics-pharma partnership model common in the precision oncology sector.

Headlines to Watch Out For

Shield CRC screening volume accelerates post Medicare coverage
Guardant360 companion diagnostic deals boost biopharma revenue
Path to gross margin expansion drives profitability timeline

Piotroski VR-10 (Strict) 2.5

Net Income: -453.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.15 > 0.02 and ΔFCF/TA 3.37 > 1.0
NWC/Revenue: 86.69% < 20% (prev 77.82%; Δ 8.87% < -1%)
CFO/TA -0.10 > 3% & CFO -185.2m > Net Income -453.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.03 > 1.5 & < 3
Outstanding Shares: last quarter (132.1m) vs 12m ago 6.41% < -2%
Gross Margin: 65.01% > 18% (prev 62.84%; Δ 2.17% > 0.5%)
Asset Turnover: 72.93% > 50% (prev 62.23%; Δ 10.71% > 0%)
Interest Coverage Ratio: -93.37 > 6 (EBIT TTM -449.7m / Interest Expense TTM 4.82m)

Altman Z'' -3.95

A: 0.54 (Total Current Assets 1.36b - Total Current Liabilities 339.0m) / Total Assets 1.91b
B: -1.69 (Retained Earnings -3.23b / Total Assets 1.91b)
C: -0.28 (EBIT TTM -449.7m / Avg Total Assets 1.62b)
D: -0.10 (Book Value of Equity -222.9m / Total Liabilities 2.14b)
Altman-Z'' = -3.95 = D

Beneish M -2.88

DSRI: 0.78 (Receivables 144.2m/130.3m, Revenue 1.18b/828.8m)
GMI: 0.97 (GM 62.84% / 65.01%)
AQI: 1.12 (AQ_t 0.13 / AQ_t-1 0.11)
SGI: 1.43 (Revenue 1.18b / 828.8m)
TATA: -0.14 (NI -453.4m - CFO -185.2m) / TA 1.91b)
Beneish M = -2.88 (Cap -4..+1) = A

What is the price of GH shares?

As of August 11, 2026, the stock is trading at USD 167.21 with a total of 1,504,516 shares traded. Over the past week, the price has changed by +5.28%, over one month by +4.47%, over three months by +72.90% and over the past year by +205.13%.

Current recommended Stop Loss: 156.80 (which is 6.2% or 1.2 ATR below the current price).

Is GH a buy, sell or hold?

Guardant Health has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy GH.

StrongBuy: 18
Buy: 4
Hold: 0
Sell: 1
StrongSell: 0

What are the forecasts/targets for the GH price?

Analysts Target Price	194.3	16.2%

Guardant Health (GH) - Fundamental Data Overview as of 10 August 2026

Market Cap USD = 22.6b (22.6b USD * 1.0 USD.USD)
P/S = 19.1102
P/B = 55.6696
Revenue TTM = 1.18b USD
EBIT TTM = -449.7m USD
EBITDA TTM = -411.2m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 27.8m USD (from shortTermDebt, last quarter)
Debt = 1.89b USD (from shortLongTermDebtTotal, last quarter) + Leases 194.1m
Net Debt = 837.6m USD (calculated: Debt 1.89b - CCE 1.05b)
Enterprise Value = 23.4b USD (22.6b + Debt 1.89b - CCE 1.05b)
Interest Coverage Ratio = -93.37 (Ebit TTM -449.7m / Interest Expense TTM 4.82m)
EV/FCF = -83.98x (Enterprise Value 23.4b / FCF TTM -279.2m)
FCF Yield = -1.19% (FCF TTM -279.2m / Enterprise Value 23.4b)
FCF Margin = -23.60% (FCF TTM -279.2m / Revenue TTM 1.18b)
Net Margin = -38.33% (Net Income TTM -453.4m / Revenue TTM 1.18b)
Gross Margin = 65.01% ((Revenue TTM 1.18b - Cost of Revenue TTM 413.9m) / Revenue TTM)
Gross Margin QoQ = 65.39% (prev 65.22%)
Tobins Q-Ratio = 12.26 (Enterprise Value 23.4b / Total Assets 1.91b)
Interest Expense / Debt = 0.25% (Interest Expense 4.82m / Debt 1.89b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -355.2m (EBIT -449.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.16 (Total Current Assets 1.36b / Total Current Liabilities 432.5m)
Debt / Equity = -8.49 (negative equity) (Debt 1.89b / totalStockholderEquity, last quarter -222.9m)
Debt / EBITDA = -2.04 (negative EBITDA) (Net Debt 837.6m / EBITDA -411.2m)
Debt / FCF = -3.00 (negative FCF - burning cash) (Net Debt 837.6m / FCF TTM -279.2m)
Total Stockholder Equity = -214.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.95% (Net Income -453.4m / Total Assets 1.91b)
RoE = 211.5% (negative equity) (Net Income TTM -453.4m / Total Stockholder Equity -214.4m)
RoCE = -34.90% (EBIT -449.7m / Capital Employed (Equity -214.4m + L.T.Debt 1.50b))
RoIC = -23.04% (negative operating profit) (NOPAT -355.2m / Invested Capital 1.54b)
WACC = 9.64% (E(22.6b)/V(24.5b) * Re(10.43%) + D(1.89b)/V(24.5b) * Rd(0.25%) * (1-Tc(0.21)))
Discount Rate = 10.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.04 | Cagr: 3.70%
[DCF] Fair Price = unknown (Cash Flow -279.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.46 | # QB: -1
Revenue Correlation: 99.64 | Revenue CAGR: 32.73% | SUE: 3.10 | # QB: 9
EPS current Quarter (2026-09-30): EPS=-0.30 | Chg30d=+0.20% | Revisions=+17% | Analysts=17
EPS current Year (2026-12-31): EPS=-1.45 | Chg30d=-3.83% | Revisions=+17% | GrowthEPS=+20.1% | GrowthRev=+38.0%
EPS next Year (2027-12-31): EPS=-0.45 | Chg30d=+5.18% | Revisions=+10% | GrowthEPS=+69.0% | GrowthRev=+35.0%
[Analyst] Revisions Ratio: +19% (up=8, down=5)